Stock Analysis: Johnson & Johnson (JNJ)

Johnson & Johnson engages in the manufacture and sale of various products in the health care field worldwide.

There is no perfect dividend growth stock, but JNJ comes close. The company enjoys a diverse revenue base, an excellent research pipeline, a pristine balance sheet and exceptional free cash-flows to cover it dividend. This diversity and strength will help the company overcome near-term results from patent losses on Risperdal and Topamax. I will continue to add to my position as my allocation allows and when JNJ is trading below my buy price of $70.24.

Source: Dividends Value


Related Articles:

• Owens & Minor, Inc. (OMI) Dividend Stock Analysis
  
• The Procter & Gamble Company (PG) Dividend Stock Analysis
  
• Stock Analysis: Abbott Laboratories (ABT)
  
• Colgate-Palmolive Company (CL) Dividend Stock Analysis
  
• More Analysis